Navigation Links
Pharmacyclics to Present at the 8th Annual Needham and Company Life Sciences Conference
Date:6/5/2009

SUNNYVALE, Calif., June 5 /PRNewswire-FirstCall/ -- Pharmacyclics, Inc. (Nasdaq: PCYC), a biopharmaceutical company focused on developing and commercializing innovative small molecule drugs for the treatment of immune mediated disease and cancer, today announced that Glenn Rice, President and COO will present on Wednesday, June 10, at 11:30 a.m. ET at the 8th Annual Needham Life Sciences Conference taking place at the New York Palace Hotel.

There will be a live webcast of the presentation, which will be accessible through a link posted on the home page and investor relations section of the PCYC website. The webcast will be available for replay through June 26, 2009.

About Pharmacyclics

Pharmacyclics(R) is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative small-molecule drugs for the treatment of immune mediated disease and cancer. The purpose of the company is to create a profitable business by generating income from products it develops, licenses and commercializes, either with one or several potential partners or alone as may best forward the economic interest of its stakeholders. The company endeavors to create novel, patentable, differentiated products that have the potential to significantly improve the standard of care in the markets it serves. Presently, Pharmacyclics has four product candidates in clinical development and two product candidates in pre-clinical development. It is Pharmacyclics' business strategy to establish collaborations with large pharmaceutical and biotechnology companies for the purpose of generating present and future income in exchange for adding to their product pipelines. Pharmacyclics strives to generate collaborations that allow it to retain valuable territorial rights and simultaneously fast forward the clinical development and commercialization of its products. The Company is headquartered in Sunnyvale, California and is listed on NASDAQ under the symbol PCYC. To learn more about how Pharmacyclics advances science to improve human healthcare visit us at http://www.pharmacyclics.com.

    Contact:
    Ramses Erdtmann
    VP Finance
    408-215-3325


'/>"/>
SOURCE Pharmacyclics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Pharmacyclics Files Registration Statement for Rights Offering
2. Pharmacyclics Reports Second Quarter Fiscal 2009 Financial Results
3. Pharmacyclics Announces Appointment of New Management Team and Board Director to Accelerate Its Future Growth
4. Pharmacyclics Secures $5.0 Million in Debt Financing
5. Pharmacyclics Reports First Quarter Fiscal 2009 Financial Results
6. Pharmacyclics Reports Fourth Quarter and Fiscal 2008 Financial Results
7. Pharmacyclics Announces It Received Nasdaq Notice of Compliance
8. Pharmacyclics Announces It Received Nasdaq Notification
9. Pharmacyclics Announces Multiple Presentations at the American Association for Cancer Research Annual Meeting
10. Data for SemBioSys insulin to be presented at the American Diabetes Associations 69th Scientific Sessions
11. Poniard Pharmaceuticals to Present at the 8th Annual Needham Life Sciences Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/10/2017)... CRUZ, Calif. , Oct. 10, 2017 ... grant from the NIH to develop RealSeq®-SC (Single Cell), ... kit for profiling small RNAs (including microRNAs) from single ... Analysis Program highlights the need to accelerate development of ... "New techniques for measuring ...
(Date:10/9/2017)... ... October 09, 2017 , ... The award-winning American Farmer television ... quarter 2018. American Farmer airs Tuesdays at 8:30aET on RFD-TV. , With global ... the challenge of how to continue to feed a growing nation. At the same ...
(Date:10/7/2017)... ... October 06, 2017 , ... ... advanced instruments and applications consulting for microscopy and surface analysis, Nanoscience Instruments ... consulting, Nanoscience Analytical offers a broad range of contract analysis services for ...
(Date:10/6/2017)... (PRWEB) , ... October 06, 2017 , ... ... host a lunch discussion and webinar on INSIGhT, the first-ever adaptive clinical trial ... Investigator, Dana-Farber Cancer Institute. The event is free and open to the public, ...
Breaking Biology Technology:
(Date:4/18/2017)... 18, 2017  Socionext Inc., a global expert in SoC-based imaging ... server, the M820, which features the company,s hybrid codec technology. A ... Tera Probe, Inc., will be showcased during the upcoming Medtec Japan ... at the Las Vegas Convention Center April ... Click here for ...
(Date:4/11/2017)... , Apr. 11, 2017 Research and ... Market 2017-2021" report to their offering. ... The global eye tracking market to grow at a ... report, Global Eye Tracking Market 2017-2021, has been prepared based on ... covers the market landscape and its growth prospects over the coming ...
(Date:4/5/2017)... -- Today HYPR Corp. , leading innovator in ... the HYPR platform is officially FIDO® Certified . ... that empowers biometric authentication across Fortune 500 enterprises and ... 15 million users across the financial services industry, however ... suites and physical access represent a growing portion of ...
Breaking Biology News(10 mins):